1.03BMarket Cap-14.25P/E (TTM)
11.000High10.560Low2.30MVolume10.900Open10.860Pre Close22.53MTurnover2.71%Turnover RatioLossP/E (Static)96.36MShares19.09052wk High13.79P/B906.32MFloat Cap9.41052wk Low--Dividend TTM84.78MShs Float43.600Historical High--Div YieldTTM4.05%Amplitude0.710Historical Low9.794Avg Price1Lot Size
Avadel Pharmaceuticals Stock Forum
AVDL fell 25.2% to $8 shortly before 5 p.m. ET after the company announced that Q4 revenues will come in at $50 million – below the $52.7 million that analysts had reportedly expected.
The company like...
yeah, cluster buys drew my attention too
– Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challen...
🎃⚡️🎃
📊⚡️📊
4 mins ago
Avadel Pharmaceuticals Announces FDA Approval of Lumryz™ (Sodium Oxybate) Extended-Release Oral Suspension (Ciii) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older With Narcolepsy
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...
No comment yet